Search hospitals > District of Columbia > Washington
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Claim this profileWashington, District of Columbia 20007
Global Leader in Breast Cancer
Global Leader in Leukemia
Conducts research for Lymphoma
Conducts research for Lung Cancer
Conducts research for Cancer
377 reported clinical trials
20 medical researchers
Summary
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Leukemia, Lymphoma, Lung Cancer, Cancer and other specialties. Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is involved with conducting 377 clinical trials across 298 conditions. There are 20 research doctors associated with this hospital, such as Benjamin A. Weinberg, Claudine Isaacs, MD, Stephen V. Liu, and Paula Pohlmann, MD, PhD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Leukemia
Global LeaderTop PIs
Benjamin A. WeinbergMedStar Georgetown University Hospital1 year of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
17 reported clinical trials
35 drugs studied
Claudine Isaacs, MDGeorgetown University3 years of reported clinical research
Studies Breast Cancer
Studies Tumors
12 reported clinical trials
30 drugs studied
Stephen V. LiuMedStar Georgetown University Hospital7 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
22 drugs studied
Paula Pohlmann, MD, PhDLombardi Cancer Center / Georgetown University Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Tumors
10 reported clinical trials
18 drugs studied
Clinical Trials running at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Tumors
Pancreatic Cancer
KRAS Mutation
Colorectal Cancer
Small Cell Lung Cancer
Melanoma
Adenocarcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Recruiting1 award Phase 219 criteria
Durvalumab + Tremelimumab with Chemotherapy
for Non-Small Cell Lung Cancer
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection (cohort 1) or hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (cohort 2) will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in patients with HIV, HBV, or HCV infection.
Recruiting1 award Phase 218 criteria
Anti-CD38 + KRAS Vaccine + Anti-PD-1
for Pancreatic & Lung Cancer
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of cancer? * How well does participants bodies handle these study drugs? * Does this combination of study drugs help participants live longer? Participants will receive daratumumab, nivolumab with KRAS vaccine and have regular tests and procedures to follow how the participants are doing on these study drugs.
Recruiting1 award Phase 213 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center?
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Leukemia, Lymphoma, Lung Cancer, Cancer and other specialties. Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is involved with conducting 377 clinical trials across 298 conditions. There are 20 research doctors associated with this hospital, such as Benjamin A. Weinberg, Claudine Isaacs, MD, Stephen V. Liu, and Paula Pohlmann, MD, PhD.
Where is Lombardi Comprehensive Cancer Center at Georgetown University Medical Center located?
The Lombardi Comprehensive Cancer Center, situated at 3970 Reservoir Road NW, Washington, D.C., is affiliated with MedStar Georgetown University Hospital and focuses on advancing cancer research. It offers a comprehensive range of cancer care services, from screening and prevention to diagnosis, treatment, rehabilitation, and survivorship programs. This center is an integral part of the Georgetown University Medical Center.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center:
- **MedStar Health Home Care Patient Financial Services:** Call 301-931-6125 or toll-free at 877-931-3100 ext. 6125.
- **Hospital Billing Concerns:** Call 410-933-2424 or toll-free at 800-280-9006.
- **Physician Billing Concerns:** Call 703-558-1400 or toll-free at 888-896-1400.
What insurance does Lombardi Comprehensive Cancer Center at Georgetown University Medical Center accept?
The Lombardi Comprehensive Cancer Center, located within MedStar Georgetown University Hospital, accepts most major health insurance plans. Coverage for specific services may vary, so patients are advised to contact their insurance provider to confirm coverage details.
What awards or recognition has Lombardi Comprehensive Cancer Center at Georgetown University Medical Center received?
Lombardi Comprehensive Cancer Center, located at Georgetown University Medical Center in Washington, D.C., is distinguished as the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the area. It serves as the research cornerstone for the MedStar Georgetown Cancer Institute. Additionally, it collaborates with John Theurer Cancer Center at Hackensack University Medical Center in New Jersey as part of an NCI Comprehensive Cancer Center research consortium, emphasizing studies on innovative cancer treatments and technologies to improve patient outcomes.